Logo 1 Logo 2

Clinical Trial Details

Trial ID: L1597
Source ID: NCT01356615
Associated Drug: Low Molecular Weight Heparin (Enoxaparin Sodium)
Title: Low Molecular Weight Heparin for Hemodialysis Anticoagulation
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: End Stage Renal Failure on Dialysis
Interventions: DRUG: low molecular weight heparin (enoxaparin sodium)|DRUG: standard unfractionated heparin
Outcome Measures: Primary: Fibrin/clot formation in the dialyzer and Hemorrhage in Dialysis by visual inspection, The frequency and degree of clot and fibrin formation in both the dialyzer and lines were scored on a 10-point scale, with 1 indicating no clot formation and 10 sever clotting or total occlusion. This assessment was done after the blood had been returned to the patient by flushing the dialyzer and lines with normal saline. Hemorrhage or thrombosis, during and between dialyses was also noted. Heparin anticoagulation, Clinical clotting and Hemorrhage were evaluated by visual inspection. Hemorrhages were categorized as weak, moderate, and severe., 3 month | Secondary: changes in serum Cholesterol,low and High Density Lipoprotein and Triglycerid., 27 chronic HD patients. They were randomly assigned to either Clexane (40 mg) or standard heparin, and followed prospectively for 3 months (36 dialyses) and then crossed over to the alternate therapy for a further 3 months Fasting standard lipid profiles were determined at the end of each arm of the study. Total cholesterol (TC), high density lipoprotein (HDL), and triglyceride (TG) were measured., 3 month
Sponsor/Collaborators: Sponsor: Tehran University of Medical Sciences
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases:
Enrollment: 27
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: PREVENTION
Start Date: 2011-03
Completion Date: 2011-03
Results First Posted:
Last Update Posted: 2011-05-19
Locations:
URL: https://clinicaltrials.gov/show/NCT01356615